Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis.

ScFv-hIL-22 and hIL-22-GLP1 had lesser effects on tunicamycin-induced ER stress and alterations in proinsulin that did not reach statistical significance (Fig. 2f ).

also in 111,027 other papers